AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25393877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), Ursodeoxycholic acid (UDCA), and low-dose low molecular weight heparin (LMWH) for 8 weeks
Number of subjects: 22
Study 25393877 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 22
Study 24126611 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and behavioral weight loss (750 vs. >3000 kcal/week)
Number of subjects: 46
Study 21084988 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal band ligation (VBL)
Number of subjects: 38
Study 21084988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection (CI)
Number of subjects: 38
Study 18306109 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Hsp-G administered every morning for 12 weeks (n = 9)
Number of subjects: 19
Study 18306109 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every morning for 12 weeks (n = 10)
Number of subjects: 19
Study 17186321 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate concentration contrast medium (300 mg I/ml)
Number of subjects: 945
Study 17186321 — intervention group
Group type: COMPARATOR
Intervention: High concentration contrast medium (370 mg I/ml)
Number of subjects: 945
Study 12707842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy programme (16 group sessions of 90 min each)
Number of subjects: 122
Study 12707842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy programme
Number of subjects: 122
Study 12707842 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 122
Study 10977001 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day) for 2 years
Number of subjects: 65
Study 10977001 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day) for 12 months followed by calcium for 12 months
Number of subjects: 65
Study 10977001 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 65
Study 10977001 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5‐0.75 microg/day)
Number of subjects: 65
Study 10977001 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol therapy
Number of subjects: 65
Study 9358940 — intervention group
Group type: EXPERIMENTAL
Intervention: O + M + MPZ
Number of subjects: 338
Study 9358940 — intervention group
Group type: COMPARATOR
Intervention: O + M
Number of subjects: 338
Study 1490453 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 60
Study 1490453 — intervention group
Group type: COMPARATOR
Intervention: Iopentol
Number of subjects: 60
Study 1490453 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 60
Study 3885979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol (54 patients)
Number of subjects: 106
Study 3885979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (52 patients)
Number of subjects: 106
Study 31128568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 31128568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Number of subjects: 0
Study 31128568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29402341 — intervention group
Group type: EXPERIMENTAL
Intervention: 19AL (finished indoors on concentrates ad libitum for 100 days)
Number of subjects: 90
Study 29402341 — intervention group
Group type: COMPARATOR
Intervention: 19SP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 100 days)
Number of subjects: 90
Study 29402341 — intervention group
Group type: COMPARATOR
Intervention: 19LP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 150 days)
Number of subjects: 90
Study 29402341 — intervention group
Group type: EXPERIMENTAL
Intervention: 24MO (finished indoors over the second winter on grass silage ad libitum plus 5 kg DM of concentrate per head daily)
Number of subjects: 90
Study 29402341 — intervention group
Group type: COMPARATOR
Intervention: 21SP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 60 days)
Number of subjects: 90
Study 29402341 — intervention group
Group type: COMPARATOR
Intervention: 21LP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 110 days)
Number of subjects: 90
Study 29402341 — intervention group
Group type: EXPERIMENTAL
Intervention: 21LP
Number of subjects: 90
Study 27691979 — intervention group
Group type: EXPERIMENTAL
Intervention: Child maltreatment (maltreated children)
Number of subjects: 548
Study 24933799 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP)
Number of subjects: 30
Study 24933799 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (silica-based) containing 1450 ppm fluoride as sodium monofluorophosphate (MFP)
Number of subjects: 30
Study 22357140 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin 1.8 mg/m² intravenously over 1 hour every 3-4 weeks (initially 1.3 mg/m² for first three adults and three children)
Number of subjects: 49
Study 22357140 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (first course 1.3 mg/m²)
Number of subjects: 49
Study 19962744 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 18
Study 19962744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17356305 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of early meconium evacuation by routine glycerin enema
Number of subjects: 0
Study 17356305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early meconium evacuation)
Number of subjects: 0
Study 15848699 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab dosing strategies
Number of subjects: 297
Study 15848699 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction
Number of subjects: 297
Study 11990212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 921
Study 11990212 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 921
Study 9523410 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-promotion in female targets
Number of subjects: 0
Study 9523410 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-effacement in male targets
Number of subjects: 0
Study 7648980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 350 mg/day for two weeks
Number of subjects: 30
Study 7648980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1400 mg/day for two weeks
Number of subjects: 30
Study 7648980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2744905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (0.4 mg)
Number of subjects: 16
Study 2744905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29845901 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-based dietary intervention
Number of subjects: 148
Study 28629471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and agricultural support activities alongside the routine provision of Save the Children's ECD programme
Number of subjects: 60
Study 28629471 — intervention group
Group type: COMPARATOR
Intervention: Control group attending CBCCs supported by Save the Children's Early Childhood Health and Development (ECD) programme
Number of subjects: 60
Study 25898472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone in oil 100 mg daily
Number of subjects: 584
Study 25898472 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized progesterone followed by compounded vaginal progesterone 200 mg 3 times daily (OV)
Number of subjects: 584
Study 23141881 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray (n=39)
Number of subjects: 43
Study 23141881 — intervention group
Group type: EXPERIMENTAL
Intervention: THC oromucosal spray (n=4)
Number of subjects: 43
Study 20363847 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 5 cm H(2)O
Number of subjects: 11
Study 20363847 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 10 cm H(2)O
Number of subjects: 11
Study 20363847 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 15 cm H(2)O
Number of subjects: 11
Study 20363847 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 11
Study 18699801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg twice daily for 14 days
Number of subjects: 11
Study 18699801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 11
Study 18699801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16912977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 55
Study 16912977 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser resurfacing
Number of subjects: 55
Study 12809168 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, low-volume and moderate-intensity exercise training (IET)
Number of subjects: 30
Study 12809168 — intervention group
Group type: COMPARATOR
Intervention: Non-specific, high-volume, low-intensity exercise training (NET)
Number of subjects: 30
Study 10917990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruitt-Inahara shunt
Number of subjects: 548
Study 8815753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methylprednisolone and cyclophosphamide)
Number of subjects: 82
Study 8815753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 82
Study 8815753 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 82
Study 8815753 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs Methylprednisolone
Number of subjects: 82
Study 1519208 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1,200 mg/day
Number of subjects: 63
Study 1519208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 6395276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1.0 g once daily intramuscularly or intravenously)
Number of subjects: 57
Study 6395276 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (0.5‐1.0 g three times a day intramuscularly or intravenously)
Number of subjects: 57
Study 30925575 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy augmented by MMC and beta radiation (1000 cGy, strontium-90 probe, 5-7 days preoperatively)
Number of subjects: 50
Study 30925575 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with MMC alone
Number of subjects: 50
Study 28064099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Programme (ERP)
Number of subjects: 86
Study 28064099 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative care
Number of subjects: 86
Study 26795772 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment approach training
Number of subjects: 103
Study 26795772 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 103
Study 24766062 — intervention group
Group type: COMPARATOR
Intervention: Primary care treatment
Number of subjects: 1300
Study 24766062 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary care treatment
Number of subjects: 1300
Study 22437282 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLR)
Number of subjects: 100
Study 22437282 — intervention group
Group type: COMPARATOR
Intervention: Medial retinaculum plication (MRP)
Number of subjects: 100
Study 19160053 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program dissemination
Number of subjects: 18
Study 19160053 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual control condition
Number of subjects: 18
Study 16769235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (PXT) 30 mg tid for two weeks
Number of subjects: 19
Study 16769235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14740955 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations 1-15 (10^5-6 PFU/dose or 10^3.5-4.5 PFU/dose)
Number of subjects: 64
Study 10766487 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation of patients with cancer (experimental group)
Number of subjects: 233
Study 10766487 — intervention group
Group type: COMPARATOR
Intervention: Patients with other diagnoses (control group)
Number of subjects: 233
Study 9467328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 2.5 Hz
Number of subjects: 60
Study 9467328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 5 Hz
Number of subjects: 60
Study 9467328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phototherapy/low-intensity laser therapy (CLILT) at 20 Hz
Number of subjects: 60
Study 9467328 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 9467328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 1593244 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine system
Number of subjects: 186
Study 1593244 — intervention group
Group type: COMPARATOR
Intervention: Placebo system
Number of subjects: 186
Study 3914023 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 infusion (10 mg/kg.min for 24 hours)
Number of subjects: 14
Study 3914023 — intervention group
Group type: COMPARATOR
Intervention: Solvent (glycine buffer)
Number of subjects: 14
Study 30590701 — intervention group
Group type: EXPERIMENTAL
Intervention: AGO2 loading with G-rich sequences
Number of subjects: 2
Study 30590701 — intervention group
Group type: EXPERIMENTAL
Intervention: AGO1 loading with GAC motif
Number of subjects: 2
Study 30590701 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Ago2 loading
Number of subjects: 2
Study 30269054 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 177
Study 27445558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 49
Study 27445558 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 49
Study 27445558 — intervention group
Group type: COMPARATOR
Intervention: Chest Transillumination (CTR)
Number of subjects: 49
Study 24999670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 87
Study 24999670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 87
Study 24999670 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 87
Study 24999670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)
Number of subjects: 87
Study 22744848 — intervention group
Group type: EXPERIMENTAL
Intervention: Folliculo-luteal function (FLF) normalized preconceptionally
Number of subjects: 110
Study 22744848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 19931154 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (loading dose of 1 mg/kg over 15 minutes followed by maintenance of 1 to 3 mg/kg per hour)
Number of subjects: 40
Study 19931154 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (loading dose of 1 microg/kg over 10 minutes followed by maintenance of 0.2 to 2.5 microg/kg per hour)
Number of subjects: 40
Study 17707724 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate vaginal gel
Number of subjects: 54
Study 17707724 — intervention group
Group type: COMPARATOR
Intervention: K-Y Jelly
Number of subjects: 54
Study 16369716 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving indicator underglove system (IUS)
Number of subjects: 100
Study 16369716 — intervention group
Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 100
Study 12792790 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (460 mg/m(2)/day) + PSK (3 g/day)
Number of subjects: 558
Study 12792790 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU (115 mg/m(2)/day) + PSK (3 g/day)
Number of subjects: 558
Study 10958722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent film dressing for 2 days
Number of subjects: 100
Study 10958722 — intervention group
Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 100
Study 8781697 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of vaginal prostaglandin E2 as outpatient treatment
Number of subjects: 200
Study 8781697 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with twice weekly surveillance tests
Number of subjects: 200
Study 1486421 — intervention group
Group type: EXPERIMENTAL
Intervention: POSSUM
Number of subjects: 117
Study 1486421 — intervention group
Group type: COMPARATOR
Intervention: APACHE II
Number of subjects: 117
Study 6729259 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline theophyllinate, 600 mg orally
Number of subjects: 19
Study 31898323 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH forgiveness collectivistic (REACH-FC) intervention
Number of subjects: 97
Study 31898323 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 97
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT (2×20 s 'all-out' sprints, time commitment 10 min)
Number of subjects: 11
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (30 min of continuous exercise)
Number of subjects: 11
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (10×1 min at 90 HRmax, time commitment 25 min)
Number of subjects: 11
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT
Number of subjects: 11
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 11
Study 30171349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 11
Study 30171349 — intervention group
Group type: COMPARATOR
Intervention: CON (no exercise)
Number of subjects: 11
Study 27476505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained tutors
Number of subjects: 197
Study 24999104 — intervention group
Group type: EXPERIMENTAL
Intervention: Common atropine (CA) gel
Number of subjects: 18
Study 24999104 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified atropine (MA) gel
Number of subjects: 18
Study 23316285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-output LV pacing (Lo)
Number of subjects: 39
Study 23316285 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output LV pacing (Hi)
Number of subjects: 39
Study 20033622 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care (GC)
Number of subjects: 904
Study 20033622 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 904
Study 18821457 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with symptoms consistent with Cluster B pathology
Number of subjects: 54
Study 18821457 — intervention group
Group type: COMPARATOR
Intervention: Participants without Cluster B pathology
Number of subjects: 54
Study 16020076 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (16-week duration)
Number of subjects: 10
Study 12445065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted resection
Number of subjects: 170
Study 12445065 — intervention group
Group type: COMPARATOR
Intervention: Open operation
Number of subjects: 170
Study 10442679 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor as first-line treatment
Number of subjects: 0
Study 10442679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic added to ACE inhibitor
Number of subjects: 0
Study 10442679 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 10442679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0
Study 10442679 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, diuretics, beta-blockers (e.g. carvedilol), and digoxin
Number of subjects: 0
Study 8557009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide at 620 micrograms kg‐1
Number of subjects: 20
Study 8557009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide at 930 micrograms kg‐1
Number of subjects: 20
Study 8557009 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 20
Study 8557009 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 20
Study 1837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 12
Study 1837629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6262702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride infusion
Number of subjects: 0
Study 30668228 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic diabetes support intervention
Number of subjects: 0
Study 30668228 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive face-to-face care
Number of subjects: 0
Study 28697769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nurse-delivered intervention (IPV screening, supportive referrals, health/safety risk assessments at baseline and a booster session after 3 months)
Number of subjects: 950
Study 28697769 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nurse-delivered intervention
Number of subjects: 950
Study 28697769 — intervention group
Group type: COMPARATOR
Intervention: Control group (screening and referral card from nurses)
Number of subjects: 950
Study 28697769 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 950
Study 25119117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 128
Study 25119117 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled opioid-based analgesia (PCA)
Number of subjects: 128
Study 23256148 — intervention group
Group type: EXPERIMENTAL
Intervention: Child HIV infection, preterm birth, stunting, and wasting
Number of subjects: 311
Study 21242784 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% Mitomycin C (MMC)
Number of subjects: 28